This 2006 review article distinguishes between “jealous love” (trait jealousy) and “morbid jealousy” (state jealousy). Jealous love is characterized by an intense desire for exclusive possession of a partner, often accompanied by a need to scrutinize the partner’s thoughts and behaviors for signs of infidelity, even in the absence of
This 2018 review by Maroon and Bost examines the therapeutic potential of phytocannabinoids, particularly cannabidiol (CBD) and delta-9-tetrahydrocannabinol (Δ9-THC), in various neurological disorders. The authors highlight the neuroprotective, anti-inflammatory, and immunomodulatory properties of these compounds, which interact with the endocannabinoid system (ECS) to influence physiological processes. Clinical and preclinical studies
This systematic review and meta-analysis evaluated the safety profile of oral naltrexone by analyzing serious adverse events (SAEs) reported in placebo-controlled randomized controlled trials (RCTs). A total of 89 RCTs involving 11,194 participants across various conditions—including alcohol use disorders, psychiatric disorders, impulse control disorders, obesity, Crohn’s disease, fibromyalgia, and cancer—were
This meta-analysis examined the association between MTHFR 677C>T and 1298A>C polymorphisms and psychiatric disorders like ADHD, bipolar disorder, and schizophrenia. The study found a weak but significant association between these genetic variations and the disorders, though the strength of the association varied across studies and populations. The findings suggest a
This systematic review explores the broad therapeutic potential of cannabidiol (CBD) in the treatment of psychiatric disorders such as anxiety, depression, and psychosis. It synthesizes data from multiple in vivo studies and highlights that CBD exerts its beneficial effects through several mechanisms, including facilitating 5-HT1A receptor-mediated neurotransmission, potentiating anandamide-mediated pathways
This in vitro study examined the inhibitory effects of five structural analogues of methylene blue (MB)—neutral red, Nile blue, new methylene blue, cresyl violet, and 1,9-dimethyl methylene blue—on human monoamine oxidase (MAO) enzymes. The results demonstrated that all analogues selectively inhibited the MAO-A isoform, with cresyl violet (IC₅₀ = 0.0037
